Initial Salvage Approaches for Relapsed/Refractory Mantle Cell Lymphoma Have Comparable Response Rates, Progression-Free and Overall Survival

被引：0
|
作者：
Caulfield, Sarah
Schlafer, Danielle
Switchenko, Jeffrey M.
Greenwell, Irl Brian
Staton, Ashley D.
Blum, Kristie A.
Grover, Natalie
Park, Steven I.
Danilov, Alexey
Epperla, Narendranath
Fenske, Timothy S.
Hamadani, Mehdi
Gordon, Max J.
Mathews, Stephanie
Valla, Kelly
Flowers, Christopher
Cohen, Jonathon B.
机构：
来源：
BLOOD | 2017年 / 130卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1505
引用
收藏
页数：4
相关论文
共 50 条
  • [1] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 147 - 148
  • [2] Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.
    Greenwell, I. Brian
    Staton, Ashley Darnell
    Lee, Michael J.
    Switchenko, Jeffrey M.
    Maly, Joseph J.
    Blum, Kristie A.
    Grover, Natalie Sophia
    Mathews, Stephanie
    Park, Steven I.
    Gordon, Maxj
    Danilov, Alexey Valeryevich
    Flowers, Christopher
    Cohen, Jonathon Brett
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Lenalidomide Improves Progression-Free Survival in Mantle Cell Lymphoma
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 195 - 195
  • [4] Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma
    Dimopoulos M.
    Sonneveld P.
    Manier S.
    Lam A.
    Roccia T.
    Schecter J.M.
    Cost P.
    Pacaud L.
    Poirier A.
    Tremblay G.
    Lan T.
    Valluri S.
    Kumar S.
    [J]. BMC Cancer, 24 (1)
  • [5] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M.
    Sonneveld, P.
    Nahi, H.
    Kumar, S.
    Hashim, M.
    Kulakova, M.
    Duran, M.
    Heeg, B.
    Lam, A.
    Dearden, L.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A408 - A408
  • [6] RELATIONSHIP BETWEEN OVERALL RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) IN CLINICAL TRIALS OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
    Jen, M. H.
    Sonksen, M.
    Hess, L.
    Bian, F.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S44 - S44
  • [7] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    [J]. HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [8] Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
    Merino, Margret
    Kasamon, Yvette
    Theoret, Marc
    Pazdur, Richard
    Kluetz, Paul
    Gormley, Nicole
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2706 - +
  • [9] Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma
    Schuyler, Devon
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 915 - 915
  • [10] Correlations between overall response rate, progression-free survival and overall survival in refractory small cell lung cancer treated with lurbinectedin
    Wasifuddin, Mustafa
    Ilerhunmwuwa, Nosakhare Paul
    Hakobyan, Narek
    Tahir, Muhammad
    Abowali, Hesham
    Avezbakiyev, Boris
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345